News
CLLKF
2.400
NaN%
--
BICO Group AB reports Q3 results
Seeking Alpha · 2d ago
Bico Group upgraded to Buy from Hold at DNB Carnegie
TipRanks · 2d ago
BICO Group Earnings Call: Growth Meets Cash Flow Strain
TipRanks · 3d ago
BICO Launches 2030 Strategy, Changes Executive Management
TipRanks · 3d ago
BICO reports Q3 sales growth and higher adjusted EBITDA
TipRanks · 3d ago
Weekly Report: what happened at CLLKF last week (1102-1106)?
Weekly Report · 5d ago
BICO to Present Third-Quarter 2026 Interim Report
TipRanks · 11/06 06:35
BICO Calls Extraordinary Meeting to Propose Board Changes
TipRanks · 11/03 06:33
Weekly Report: what happened at CLLKF last week (1026-1030)?
Weekly Report · 11/02 09:50
Weekly Report: what happened at CLLKF last week (1019-1023)?
Weekly Report · 10/26 09:50
Weekly Report: what happened at CLLKF last week (1012-1016)?
Weekly Report · 10/19 09:50
Weekly Report: what happened at CLLKF last week (1005-1009)?
Weekly Report · 10/12 09:53
Weekly Report: what happened at CLLKF last week (0928-1002)?
Weekly Report · 10/05 09:53
BICO folds Cellenion into SCIENION to sharpen precision biotech focus
TipRanks · 10/02 05:32
Weekly Report: what happened at CLLKF last week (0921-0925)?
Weekly Report · 09/28 09:49
Weekly Report: what happened at CLLKF last week (0914-0918)?
Weekly Report · 09/21 09:50
Weekly Report: what happened at CLLKF last week (0907-0911)?
Weekly Report · 09/14 09:53
Weekly Report: what happened at CLLKF last week (0831-0904)?
Weekly Report · 09/07 09:49
Weekly Report: what happened at CLLKF last week (0824-0828)?
Weekly Report · 08/31 09:53
BICO Group Earnings Call: Margins Up, Risks Linger
TipRanks · 08/29 00:23
More
Webull provides a variety of real-time CLLKF stock news. You can receive the latest news about Bico Grp through multiple platforms. This information may help you make smarter investment decisions.
About CLLKF
BICO Group AB, previously Cellink AB is a Sweden-based company, which is primarily involved in the healthcare industry. The Company focuses on the application areas of bioprinting, multiomics, cell line development, and diagnostics. The Company develops and markets technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. The Company’s operations divided in two segments: The Industrial Solutions segment that offers products within precision dispensing and biosensor technology for industrial customers, which make a high-capacity contribution to customers production; and The Laboratory Solutions segment that offers 3Dprinters, single- cell and liquid- dispensing instruments as well as services and consumables related to these products.